New oral drugs in older patients: A review of idarubicin in elderly patients

Diana Crivellari, Davide Lombardi, Simon Spazzapan, Andrea Veronesi, Giuseppe Toffoli

Research output: Contribution to journalArticlepeer-review

Abstract

Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.

Original languageEnglish
Pages (from-to)153-163
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2004

Keywords

  • Elderly breast cancer patients
  • Oral anthracyclines
  • Oral idarubicin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'New oral drugs in older patients: A review of idarubicin in elderly patients'. Together they form a unique fingerprint.

Cite this